Except the majority of the cutting edge R&D is done and/or funded via the public sector.
Their R&D budget priorities are more focused on things like reformulating existing drugs to extend the patents and prevent opening the market to generic manufacturers.
So yes, cheating patent laws and heavily spending on marketing and lobbying campaigns does eat into their profit margins a little bit.
But I’m not sure how that justifies their unparalleled track record of pathologically sadistic business practices, such as the one highlighted in this article.